EICHORCondition: Chronic Lymphocytic Leukemia · Mantle Cell Lymphoma · Follicular Lymphoma · Sponsor: Merck Sharp & Dohme LLC
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
The purpose of this study is to assess the safety and tolerability of zilovertamab vedotin as monotherapy and in combination in participants with select B-cell lymphomas including mantle cell lymphoma (MCL), Richter's transformation lymphoma (RTL), follicular lymphoma (FL), and chronic lymphocytic leukemia (CLL). This study will also evaluate zilovertamab vedotin as monotherapy and in combination with respect to objective response rate. * Cohort A: Participants with relapsed or refractory MCL relapsed or refractory disease after at least 2 prior systemic therapies including a Bruton's tyrosine kinase inhibition/inhibitor (BTKi), and post therapy chimeric antigen receptor T (CAR-T) cell therapy or ineligible for CAR-T cell therapy * Cohort B: Participants with relapsed or refractory RT disease after at least 1 prior systemic therapy * Cohort C: Participants with relapsed or refractory MCL relapsed or refractory disease after at least 1 prior systemic therapy and no prior exposure to a non-covalent BTKi * Cohort D: Participants with relapsed or refractory FL and CLL relapsed or refractory disease after at least 2 prior systemic therapies and have no other available therapy * Cohort E: Participants with relapsed or refractory FL after at least 2 prior systemic therapies and have no other available therapy The primary study hypothesis is that zilovertamab vedotin monotherapy has an increased Objective Response Rate (ORR) per Lugano Response Criteria as assessed by blinded indep…
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Alaska Oncology and Hematology ( Site 0037) | Anchorage, Alaska, United States | — |
| Banner MD Anderson Cancer Center ( Site 0040) | Gilbert, Arizona, United States | — |
| Banner MD Anderson Cancer Center - University Medical Center Phoenix-Medical Oncology ( Site 0036) | Phoenix, Arizona, United States | — |
| University of Colorado Anschutz Medical Campus-The Center for Cancer and Blood Disorders ( Site 0008) | Aurora, Colorado, United States | — |
| Cancer Care Specialists of Illinois ( Site 0031) | Decatur, Illinois, United States | — |
| University of Kansas Medical Center-Division of Hematologic Malignancies and Cellular Therapeutics ( Site 0038) | Fairway, Kansas, United States | — |
| Norton Women's and Children's Hospital-Norton Cancer Institute - St. Matthews ( Site 0007) | Saint Matthews, Kentucky, United States | — |
| Greenebaum Comprehensive Cancer Center-Hematology & Multiple Myeloma ( Site 0010) | Baltimore, Maryland, United States | — |
| Tufts Medical Center ( Site 0024) | Boston, Massachusetts, United States | — |
| Massachusetts General Hospital ( Site 0018) | Boston, Massachusetts, United States | — |
| Dana-Farber Cancer Institute-Lymphoma ( Site 0026) | Boston, Massachusetts, United States | — |
| University of Michigan ( Site 0009) | Ann Arbor, Michigan, United States | — |
+ 96 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05458297